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Abstract
Background: Thus far, validated whole blood assays used in in vitro fibrinolysis experiments using
thromboelastometry (ROTEM) are lacking or have yet to be tested in humans.
The objective was first, to establish a standardized modified ROTEM approach to detect both hypo- and
hyperfibrinolysis. And second, to perform a technical and clinical validation of the assay.
Methods: Blood was used of healthy volunteers, patients with sepsis, patients after cardiothoracic surgery, pregnant
women, and cirrhotic liver disease patients. A whole blood tissue factor (TF) activated ROTEM assay with and
without the addition of recombinant tissue plasminogen activator (rTPA) was developed. Plasma fibrinolysis
determinants were measured in all volunteers and patients.
Results: Thirty five pM TF and additions of 125 and 175 ng/ml rTPA resulted in full lysis within 60 min in healthy
volunteers. Coefficients of variation were below 10 % without and below 20 % with rTPA addition. In sepsis the
hypofibrinolytic ROTEM profiles with 175 ng/ml rTPA were in line with the plasma determinants (high PAI-1, high
fibrinogen, low tPA activity, and high d-dimers). After cardiothoracic surgery, reduced fibrinogen and platelet levels
accounted for the reduced maximum clot firmness. The hypofibrinolytic profile is attributed to tranexamic acid use
and elevated PAI-1 levels. The lowest rTPA concentration in cirrhosis resulted in hyperfibrinolysis in only few of the
patients. In pregnancy normal profiles were found.
Discussion: Our high rTPA concentration demonstrates hypofibrinolytic profiles adequately in sepsis and after
cardiothoracic surgery. Our low rTPA concentration of 125 ng/ml seems too high for demonstrating
hyperfibrinolysis in cirrhotic liver disease.
Conclusions: We were able to present a validated whole blood ROTEM approach to fibrinolysis testing using
added rTPA, which can be of added value next to classical plasma based fibrinolysis assays.
Keywords: Blood coagulation tests, Fibrinolysis, Thrombelastography, Tissue plasminogen activator, Validation
studies
Background
Fibrinolysis is the process of degradation of a fibrin
clot into so-called fibrin degradation products (FDPs)
of which the d-dimers are best known. Following co-
agulation, tissue-type plasminogen activator (tPA)
induces fibrinolysis by activation of plasminogen into
plasmin which enzymatically degrades fibrin into
FDPs. To avoid excess clot lysis activity, the fibrino-
lytic system is under tight control of alpha 2-
antiplasmin, plasminogen activator inhibitor-1 (PAI-1),
and thrombin activated fibrinolysis inhibitor (TAFI).
However, a disbalance in pro- and antifibrinolytic fac-
tors can result in either hyper- or hypofibrinolysis,
which may contribute to the risk for bleeding or
thrombosis, respectively. In trauma and cirrhosis the
increased bleeding tendency is attributed to a hyperfi-
brinolytic state in combination with a rebalanced
* Correspondence: g.kuiper@mumc.nl
1Department of Anaesthesiology and Pain Treatment, Maastricht University
Medical Center (MUMC+), P. Debyelaan 25, PO Box 58006202 AZ Maastricht,
The Netherlands
2Department of Internal Medicine, Cardiovascular Research Institute
Maastricht, Laboratory for Clinical Thrombosis and Haemostasis, Maastricht
University Medical Center (MUMC+), Maastricht, The Netherlands
Full list of author information is available at the end of the article
© 2016 Kuiper et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kuiper et al. Thrombosis Journal  (2016) 14:1 
DOI 10.1186/s12959-016-0076-2
hemostatic system [1, 2]. In pregnancy, a hypercoagu-
able state may occur in conjunction with reduced
fibrinolysis [3]. In sepsis, the initial procoagulant state
is associated with attenuated fibrinolysis due to
elevated PAI-1, which may advance towards an un-
controlled syndrome of disseminated intravascular
coagulation (DIC), with a clinical bleeding tendency
[4, 5]. Factor XIII (FXIII) activated by thrombin
crosslinks fibrin strands in order to strengthen the fi-
brin clot. Low FXIII activity levels are seen in sepsis
and could contribute to an enhanced bleeding diath-
esis in severe septic shock [6].
One of the therapeutic approaches to diminish overt fi-
brinolysis is treatment with tranexamic acid, which dir-
ectly inhibits the action of plasmin. For instance, in
cardiothoracic surgery this antifibrinolytic drug is being
used to prevent and counteract extracorporeal circulation
(ECC) induced hyperfibrinolysis [7], whereas in trauma
the drug is used to diminish the bleeding tendency [8].
Both the diagnosis of the fibrinolytic state and the
management of therapeutic interventions aimed at the
fibrinolytic system could benefit from a sensitive but also
robust laboratory assay. Although most proteins and en-
zymes involved in fibrinolysis can be quantified these do
not properly reflect the dynamic status of the fibrinolytic
system. Assays developed to detect hypo- or hyperfibri-
nolysis are not commonly used in daily practice because
they are cumbersome, plasma-based and/or not suitable
for bedside assessment [9]. Several groups have modified
overall hemostatic assays such that they would become
more sensitive to changes in the fibrinolytic system. This
was achieved by modifying whole blood thrombelasto-
graphy (TEG) [10] and rotational thromboelastometry
(ROTEM) [11] by addition of recombinant TPA (rTPA)
to induce fibrinolysis ex vivo. More research has been
done using other methods or in specific patient groups
[12–21]. Overall, however, these studies lacked clinical
validation in healthy volunteers as well as defined patient
subsets with known abnormalities in coagulation and/or
fibrinolysis.
The goal for our modified ROTEM test was to use
whole blood, be tissue factor activated, have one applica-
tion with and one without the addition of rTPA, and
would have similar reproducibility in comparison to the
commercial non-modified ROTEM tissue factor acti-
vated test (EXTEM). Ideally, it would have short(er) run-
times in comparison to plasma based fibrinolysis assays
or markers, have good distinction between healthy vol-
unteers and patient groups, be easy to interpret, and
have results in line with plasma based markers for fibrin-
olysis. In this report we describe the development, the
technical, and the clinical validation of a novel whole




The institutional Ethics Committee of the Maastricht
UMC+ approved this study and of all subjects informed
consent was obtained. No compensation was given for
participation in this study. Blood of healthy volunteers
was used to validate the assay and to define reference in-
tervals, while the blood of 4 patient groups (sepsis, car-
diothoracic surgery (CTS), 3rd trimester pregnancy, and
cirrhotic liver disease Child-Pugh score B or C) was used
for clinical validation. Any notion of anticoagulation use
in a subject was reason to exclude this subject from the
study. Septic patients were recruited within 1 h after the
onset of sepsis as judged by the intensive care doctor in
charge according to current guidelines [22] after which
prompt blood withdrawal was executed. Only septic pa-
tients without signs of (non-)overt DIC were included
[23]. Cardiothoracic surgery patients were recruited be-
fore surgery. Directly after the surgery upon arrival at
the ICU blood withdrawal was done promptly. Patients
receiving heparin were antagonized with protamine in a
1:1 ratio before arrival on the ICU according to local
protocol. Females in their 3rd trimester of pregnancy
were recruited at the policlinic during regular check-ups
or at the ward before having elective caesarean section
the next day. Child-Pugh score B and C cirrhosis pa-
tients were recruited via the policlinic or at the ward
after which blood was withdrawn.
Preparation
Human recombinant tissue factor (Innovin, Dade Beh-
ring Marburg GmbH, Marburg, Germany) was reconsti-
tuted according to the manufacturer’s instructions
obtaining a 1 IU/mL concentration. This TF solution to-
gether with CaCl2 at 1 M and HN-Buffer (20 mM
HEPES, 150 mM NaCl, pH 7.7) was prepared in advance
and kept at 4–7 °C till further use.
Recombinant tPA (Actilyse, Boehringer Ingelheim,
Alkmaar, the Netherlands) was reconstituted according
to the manufacturer’s instructions (1 mg/mL or 580,000
IU/mL alteplase), immediately aliquoted, frozen, and
kept at −80 °C till further use.
The blood withdrawal was performed by venipuncture
discarding the first 3 mL or, if a radial artery catheter
was in situ, by flushing the first 5 mL before the blood
was collected in vacuum tubes containing 3.2 % (w/v)
citrate (Vacutainer, Becton Dickinson BV, Breda, the
Netherlands), 11 mM citrate with 50 μg/mL corn trypsin
inhibitor (CTI, Haematologic Technologies Inc.,
Essex Junction, VT, USA) and 0.5 M citrate at pH 4.3
(TriniLIZE Stabilyte, Tcoag Ireland Limited, Bray,
Ireland). Tubes were gently mixed directly after blood
withdrawal.
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ROTEM analysis
The ROTEM device and cups and pins were from TEM
International GmbH (Munich, Germany). The device
temperature was set to 37 °C and the maximum runtime
to 120 min. TF, CaCl2, and rTPA (if applicable) were added
to 300 μL whole blood to obtain final concentrations of 35
pM TF, 10 mM CaCl2, and 0, 125, and 175 ng/mL rTPA
(which equals 0, 72.5, and 101.5 IU/mL alteplase). Total
volume of the reagents was maintained at 50 μL per cup
by applying adequate volumes of HN-buffer.
The following standard ROTEM parameters were ana-
lyzed per channel: CT (clotting time in seconds), MCF
(maximum clot firmness in millimeters), LOT (lysis on-
set time in minutes), and LT (lysis time in minutes). The
following derived parameters were calculated using the
ROTEM data: the FS (fibrinolysis speed, defined as the
decline in %/min between the LOT and LT points; thus:
FS = 75/(LTmin-LOTmin)) and the FSc (the corrected fi-
brinolysis speed in mm/min between the LOT and LT
points; thus: FSc = (amplitudeLOT-amplitudeLT)/(LTmin-
LOTmin)).
Euglobulin clot lysis time analysis (ECLT)
The euglobulin clot lysis time was performed similar to
[24]. Differently, the precipitate was dissolved in 1 ml
Veronal buffer and the reaction was started by adding 25
μl thrombin 100 U/ml. Every 10 min resolution of the
clot was assessed visually for the first two hours. After-
wards it was observed every 15 min up to two hours. If
a clot was still present at two hours, a last observation
was made at four hours.
Complete blood count
Haemoglobin, haematocrit, platelet, and white blood cell
counts were performed on a Sysmex XE-5000 (Sysmex
Nederland B.V., Etten-Leur, The Netherlands) using
citrated whole blood. Final values were adjusted for the
extra 1/9th volume of citrate present during the
measurements.
Preparation of platelet poor plasma (PPP)
Blood was spun twice to gather PPP: a first step at 2,500
g for 5 min, followed by a second step at 10,000 g for 10
min. The PPP was directly aliquot, frozen, and kept at
−80 °C till further use.
PT (prothrombin time), aPTT (activated partial
thromboplastin time), alpha 2-antiplasmin activity, plas-
minogen activity, Factor XIII activity, d-dimer level, and fi-
brinogen level
A BCS® XP System (Siemens Healthcare Diagnostic B.V.,
The Hague, The Netherlands) was used for determining
PT (Dade Innovin), aPTT (Dade actin), alpha 2-
antiplasmin activity (Berichrom α2-Antiplasmin),
plasminogen activity (Berichrom Plasminogen), factor
XIII activity (Berichrom Factor XIII), d-dimer levels
(Innovance D-Dimer), and fibrinogen levels (Multifibrin
U) in PPP according to the manufacturer’s instructions
in batches.
tPA activity, PAI-1 activity, and TAFI antigen
ELISA kits for measuring tPA activity (ZYMUPHEN tPA
Activity), PAI-1 activity (ZYMUTEST PAI-1 Activity),
and TAFI antigen (ZYMUTEST proTAFI Ag) were ac-
quired from Hyphen Biomed (Neuville-Sur-Oise, France)
and measured in PPP according to the accompanied in-
structions in batches.
Statistical analysis
Data were collected and analyzed with IBM SPSS Statis-
tics v19.0.0 (IBM Corporation, Armonk, NY, USA). Cat-
egorical data are presented as n (%), continuous data as
median and inter quartile range (IQR).
For reproducibility, coefficients of variation (CV’s) are
expressed as the ratio of the standard deviation to the
mean. Between run CV’s were calculated using 16 re-
peated measurements with blood of one withdrawal of
one healthy volunteer. For 0 ng/mL rTPA CT and MCF
values were analyzed and for 125 and 175 ng/mL rTPA
LOT and LT values besides the CT and MCF. Further-
more within run CV’s were calculated from 11 different
blood withdrawals in one person over a time span of six
months. In this case CT, MCF, LOT, and LT were
assessed at 175 ng/ml rTPA.
Optimal time from blood withdrawal to measurement
was assessed by using blood of three healthy volunteers
and keeping it at 37 °C till further use. CT, MCF, LOT,
and LT were measured using the third condition (i.e.
175 ng/mL rTPA) at 30 min, 1 h, 2 h, 3 h, and 4 h after
blood withdrawal and assessed for stability. For each
time point a new vial of CaCl2, TF, and rTPA was used.
Ninety five percent reference ranges were determined
using MedCalc v12.0® (MedCalc Software, Mariakerke,
Belgium) using data from healthy volunteers. Skewed
data were normalized first and afterwards transformed
back when calculating the 95 % reference ranges.
Mann–Whitney-U was used for comparison testing. De-
terminants of the ROTEM parameters and their 95 %
confidence interval (95 % CI) were calculated by mul-
tiple linear regression analysis assuming p < 0.05 as sta-
tistically significant. Figures were constructed using




Before establishing the optimal concentrations for the
rTPA induced fibrinolysis ROTEM assay, various
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configurations of TF and rTPA concentrations were in-
vestigated. This revealed that TF concentrations below
35 pM resulted in prolonged CT values, whereas the
MCF was hardly influenced (data not shown). Therefore,
the final TF concentration was set at 35 pM. In blood
from healthy volunteers, full clot lysis was obtained at a
final rTPA concentration of 125 ng/mL around 60 min,
while at a final concentration of 175 ng/mL rTPA full
lysis was observed around 45 min (data not shown).
These concentrations were appropriate to maintain ac-
ceptable short runtimes. At both 125 and 175 ng/mL
rTPA, ROTEM was characterized by a lower MCF com-
pared to the assay without tPA (125 ng/mL rTPA: 2 mm
(a 3.6 % decrease) and 175 ng/mL rTPA: 5 mm (a 8.4 %
decrease)), while the CT prolonged by 5 s (a 11 % in-
crease) and 7 s (a 17 % increase) respectively in compari-
son to the assay without rTPA.
Assessment of reproducibility for the different ROTEM
parameters showed between run CV’s of 9.5 % and 1.8 %
for the CT and MCF at the 0 ng/mL rTPA concentration.
Between run CV’s were 8.7 %, 4.1 %, 12.1 % and 18.8 % for
CT, MCF, LOT, and LT at the 125 ng/mL rTPA concentra-
tion and for 175 ng/mL rTPA CV’s were 12.1 %, 4.9 %,
16.6 % and 17.1 % for each parameter, respectively.
Within run CV’s showed 25 % for CT, 8.4 % for MCF,
16.0 % for LOT, and 27.2 % for LT at 175 ng/ml rTPA.
To determine whole blood stability in the assay,
ROTEM analysis was started at 30, 60, 120, 180, and 240
min after blood drawing. At 175 ng/mL rTPA, all
ROTEM derived parameters remained stable up to 4 h
after sample collection (Fig. 1). Comparable results were
obtained for the assay in the presence of 125 ng/mL
rTPA (data not shown).
Reference intervals
ROTEM analysis data from 40 healthy volunteers (male
to female ratio of 1:1) was used to calculate the 95 % ref-
erence intervals (Table 1). Age, height, body weight,
haemoglobin, and haematocrit level were higher in males
compared to females (mean difference: 25 years, 14 cm,
27.5 kg, 1.1 mmol/L, and 0.04 L/L, respectively: all p <
0.05) while platelet count, white blood cell count, and fi-
brinogen levels were not different between the two
sexes. Regarding the ROTEM parameters, CT values
were significantly different between the two sexes with
males having shorter CTs for all rTPA concentrations
(6.5, 12.8, and 14.5 s at 0, 125, and 175 ng/mL rTPA re-
spectively: all p < 0.05). Differences between males and
females were not observed for the other ROTEM param-
eters: i.e. MCF, LOT, and LT for any of the three
conditions.
Clinical validation
In total we included 21 sepsis patients, 15 cirrhosis pa-
tients, 7 females in their 3rd trimester of pregnancy, and
20 cardiothoracic surgery (CTS) patients of which one
patient did not receive tranexamic acid (this patient was
omitted from all statistical analyses).
Complete blood count (Hb, Ht, WBC, and PLT) and
measurement of PT and aPTT was performed revealing
results that are compatible for these patient groups
(Table 2).
Fig. 1 Whole blood stability when performing rTPA induced fibrinolysis on a ROTEM. Whole blood stability at room temperature (at 0,5 to 4 h
after blood drawing) of 3 healthy volunteers for ROTEM parameters at 175 ng/mL rTPA; mean per time point (±SEM); overall mean (solid
horizontal line on Y-axis) ± error margin based on CV of test (dotted horizontal lines on Y-axis); fitted line through all value points (grey declining
line). CT clotting time, CV correlation of variation, MCF maximum clot firmness, LOT lysis onset time, LT lysis time
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In Fig. 2 a comparison of the ROTEM profiles for each
patient group to the group of healthy volunteers is dis-
played. As an example, the cardiothoracic surgery pa-
tient without having had tranexamic acid was added to
this graph only.
In the absence of rTPA, the CT was shorter for cirrho-
sis (p = 0.0121), equal for pregnancy (p = 0.5289), and
longer for sepsis (p < 0.0001) and CTS (p = 0.0013) in
comparison to healthy volunteers. Although all statisti-
cally significant, none of the median clotting times of
the groups was outside the normal range established in
healthy volunteers. The MCF was lower for CTS (p =
0.0001) and cirrhosis (p = 0.0014), while it was higher in
sepsis (p = 0.0003) and pregnancy (p = 0.0008). The
MCF in sepsis and pregnancy were both statistically as
well as clinically significant in comparison to the healthy
volunteers. LOT was prolonged in sepsis (p = 0.0041)
and CTS (p = 0.0206), but was equal in cirrhosis (p=
0.1624) and pregnancy (p = 0.1279). The LT could not
be determined in any of the groups within the runtime
of 120 min.
At 125 ng/mL rTPA the LOT was prolonged in sepsis
and CTS (p < 0.001), whereas the LOT was equal in cir-
rhosis and pregnancy. The same was seen for the LT, FS,
and FSc results, noting that LT could not be reached in
any of the CTS patients as can be appreciated from
Fig. 3.
In Fig. 4, boxplots are shown for 175 ng/mL rTPA
for which the results were similar to the 125 ng/mL
condition with LOT, LT, FS, and FSc prolonged in
sepsis and CTS (p < 0.001) and equal in cirrhosis and
pregnancy.
Determinants of the cloth strength and fibrinolytic
system were assessed for each patient group and the
healthy volunteers and are presented in Fig. 5.
Median d-dimer levels were elevated (>500 ng/L) in all
patient groups, while median FXIII activity levels were
below the reference ranges in sepsis (68.1 %) and CTS
(62.3 %) only. Median plasminogen activity levels were re-
duced in sepsis (81 %) and especially in CTS (54 %) and
cirrhosis (68 %), while being elevated in a pregnant state
(178 %) when compared to healthy volunteers (119 %).
The alpha 2-antiplasmin levels were equal in pregnancy
(117 %) and sepsis (121 %) compared to healthy volunteers
(119 %), but reduced in CTS (56 %) and cirrhosis (77 %).
PAI-1 activity levels were high in all patient groups. In
those with sepsis the median PAI-1 level was 6.0 ng/mL
(IQR 1.7–17.0) and in those with pregnancy the median
level was 2.5 ng/mL (IQR 1.1–3.6). tPA activity was low in
sepsis (0.01 IU/mL) and pregnancy (0.07 IU/mL) and nor-
mal in CTS (0.96 IU/mL) and cirrhosis (1.10 IU/mL) pa-
tients. Median TAFI antigen levels were within normal
range (50–200 %) in all groups. Fibrinogen, as more a
procoagulant marker, together with platelet levels
both account for the MCF in the 0 ng/mL rTPA con-
dition with a significant Pearson correlation R of 0.71
and 0.57, respectively.
ECLT’s (shown in Fig. 6) in healthy volunteers re-
vealed a median ECLT of 95 min (IQR 76–114 min).
In sepsis 67 % had ECLT’s ≥4 h, 19 % ≥2 h and 14 %
≤2 h. All ECLT’s in the pregnant group were ≥2 h. In
cardiothoracic surgery 80 % had ECLT shorter then 2
h with a median of 85 min (IQR 71–117). In cirrho-
sis, only 13 % had ECLT ≥2 h. All the others had a
median of 50 min (IQR 30–95).
Table 1 95 % reference intervals for tissue factor stimulated
ROTEM parameters in whole blood of 40 healthy volunteers
using different concentrations of tPA
0 ng/mL rTPA 125 ng/mL rTPA 175 ng/mL rTPA
CT (s) 36–72a 33–75a 29–73a
MCF (mm) 52–70a 47–68a 39–66a
LOT (min) 73–120 26–49a 18–40a
LT (min) >120 35–77a 25–57a
FS (%/min) NA 2.5–9.8a 4.1–12.0
FSc (mm/min) NA 1.4–5.7
a 2.4–6.6a
aafter normalization and transformation
rTPA Recombinant tissue plasminogen activator, CT Clotting time, MCF
Maximum clot firmness, LOT Lysis onset time, LT, Lysis time, FS Fibrinolysis
speed, defined as the decline in %/min between the LOT and LT points thus:
FS = 75/(LTmin-LOTmin), FSc Corrected fibrinolysis speed in mm/min between
the LOT and LT points thus: FSc = (amplitudeLOT-amplitudeLT)/(LTmin-LOTmin)
Table 2 Complete blood count and PT and aPTT of the healthy volunteers and patient groups
Healthy volunteers Sepsis CTS-TXA Cirrhotic liver disease Pregnancy
Hb(mmol/L) 9.0(8.4–9.6) 6.0*(5.6–6.3) 6.2*(5.7–6.7) 7.7*(7.2–8.4) 7.8*(7.0–8.4)
Ht(L/L) 0.43(0.40–0.45) 0.29*(0.27–0.31) 0.29*(0.26–0.32) 0.38*(0.34–0.39) 0.36*(0.34–0.39)
PLT(x109/L) 178(139–212) 141(95–213) 101*(91–140) 99*(62–136) 202(127–234)
WBC(x109/L) 6.4(5.4–7.9) 20.1*(11.5–25.3) 10.7*(8.3–12.4) 5.0(4.0–7.5) 10.7*(9.3–11.7)
PT(s) 10.5(10.2–10.8) 11.5*(10.7–12.1) 11.8*(11.5–12.4) 13.3*(13.0–13.5) 9.6*(9.3–9.6)
aPTT(s) 27(26–27) 33.5*(30–42.5) 30*(28–33) 29*(29–34) 25*(23–25)
Results are median (IQR); *p < 0.05 in comparison to healthy volunteers
Hb Hemoglobin, Ht Hmatocrit, PLT Platelet count, WBC White blood cell count, PT Prothrombin time, aPTT Activated partial thromboplastin time IQR, Interquartile
ranges, CTS-TXA, Cardiothoracic surgery patients using tranexamic acid
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Discussion
We established a protocol for the ROTEM based rTPA
induced fibrinolysis assay by defining the final concen-
trations for TF, CaCl2 and rTPA using whole blood of
healthy volunteers and validated this assay, to investi-
gate, in patient cohorts their different fibrinolytic states.
The baseline assay, applying only TF and CaCl2 with
no rTPA in whole blood, showed good reproducibility
with low CV percentages similar to those reported for
the commercial EXTEM test [25], with the exception of
higher CV percentages for CT values, which can be at-
tributed to the manual pipetting process used in our
protocol. Addition of rTPA resulted in higher CV per-
centages for lysis parameters, but these were acceptable
at values below 20 %. Besides, the final concentrations of
rTPA of 125 and 175 ng/mL gave practical runtimes
below 60 min in healthy volunteers, which is advanta-
geous over plasma based fibrinolysis tests which include
centrifugation steps. One other finding is the prolonga-
tion of the CT and attenuation of the MCF by the
Fig. 2 Normal and rTPA induced fibrinolysis profiles on a ROTEM device. Median tissue factor stimulated ROTEM traces (coloured solid lines) with
different rTPA concentrations expressed as interquartile ranges (coloured dotted lines) of four patient groups compared to healthy volunteers
(black and grey). CTS-TXA cardiothoracic surgery patients using tranexamic acid, CTS-No TXA cardiothoracic surgery patient not using tranexamic
acid, rTPA recombinant tissue plasminogen activator
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addition of rTPA, which is possibly due to the earlier
start of fibrinolysis while the cloth is being still formed.
The need for manual pipetting introduced some possible
artifacts in the CT results for this study. These results
are therefore operator dependable. For example we
found that the CT results in male were shorter in com-
parison to female volunteers. This is in contrast to other
research [26], but could be explained by the fact that
manual pipetting was used.
When comparing to previous research, different con-
centrations of rTPA were chosen ranging from 50 ng/ml
[10] to 100 ng/ml [11] and from 100 U/ml [21] to 1000
U/ml [20] depending on the needs for the test. The
combination of a “low” and a “high” rTPA concentration
would provide suitable test conditions to reflect changes
in a fibrinolysis balance that might be tilted towards
hypo- or hyperfibrinolysis. One could argue that the 125
ng/mL rTPA concentration may be too high already for
diagnosing a hyperfibrinolytical state and that too much
contrast is lost. Choosing a lower concentration of
rTPA, however, resulted in longer runtimes (data not
shown), hence 125 ng/mL rTPA together with a runtime
of 60 min seemed optimal in normal individuals. The
175 ng/ml rTPA concentration was chosen as it dimin-
ished the lysis time by 25 % in normal healthy individ-
uals. However, in our patient subsets still little effects
were seen in sepsis and after cardiothoracic surgery at
175 ng/ml rTPA, however this concentration seems rea-
sonable for diagnosing hypofibrinolysis. The 125 ng/ml
concentration is proven to be too high for hyperfibrino-
lytical states. A lower concentration could improve
hyperfibrinolysis testing by sacrificing short runtimes.
One point which needs to be made is that for TEG
(trombelastography) analysis, the use of a native TEG
(non-activated) versus a RapidTEG (kaolin activated)
seems to influence fibrinolysis results [27]. Whether this
is also the case for our rTPA induced tissue factor acti-
vated ROTEM analysis is unclear.
When determining the effects of processing time from
blood sampling to ROTEM analysis, there appears to be
little effect on test outcomes within a 4-h period, which
is reasonable for clinical purposes. The 95 % reference
intervals were assessed using whole blood from 40
healthy volunteers. We decided however to normalize
Fig. 3 Boxplots of different ROTEM parameters at 125 ng/mL rTPA in healthy volunteers and patient groups. Sepsis and CTS are significantly
different to HV (p < 0.001) for all four parameters. The grey area depicts the 95 % reference ranges as was calculated using the healthy volunteer
data from Table 1. CTS-TXA cardiothoracic surgery patients using tranexamic acid, HV healthy volunteers, rTPA recombinant tissue plasminogen
activator, CT clotting time, MCF maximum clot firmness, LOT lysis onset time, LT lysis time, FS fibrinolysis speed, defined as the decline in %/min
between the LOT and LT points thus: FS = 75/(LTmin-LOTmin); FSc, corrected fibrinolysis speed in mm/min between the LOT and LT points thus:
FSc = (amplitudeLOT-amplitudeLT)/(LTmin-LOTmin)
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the results and calculate 95 % intervals and then trans-
forming them back, making the 95 % reference intervals
smaller than advised in order to correct for possible out-
liers [28]. The reference intervals in our 0 ng/mL rTPA
for CT and MCF are in line with the commercial re-
agents for the EXTEM test. The reference intervals for
the commercial EXTEM CT and MCF are 36–60s and
48–72mm respectively, as were established in our hos-
pital healthy volunteer population. Reference intervals
for LOT and LT using the EXTEM test were never
established, as these seem irrelevant in a healthy popula-
tion. LOT, LT, and other lysis index parameters (LI30,
LI45, LI60) are used in clinical practice in overt
hyperfibrinolysis.
For the clinical validation we selected patients, which
according to literature could have a hyper- or hypofibri-
nolytic potential and compared them to healthy volun-
teers. The need for an rTPA induced method of
assessing fibrinolysis in the ROTEM assay becomes ob-
vious when comparing test conditions with rTPA versus
those without rTPA addition. Within a time span of 2 h
no distinction can be made between any of the groups
and healthy population with regard to fibrinolytic poten-
tial, either visually or by using CT, MCF, LOT, or LT pa-
rameters in the absence of added rTPA. As illustrated in
Fig. 2, marked differences between healthy persons on
the one hand and different patient populations on the
other hand are detectable with added rTPA.
In subjects with sepsis but without an overt state of
DIC (according to ISTH criteria) a hypofibrinolytic state
(long LOT and LT combined with reduced FS and FSc)
in conjunction with a marked procoagulant state (high
MCF) is evident, despite the fact that high D-dimer
levels suggest a high fibrinolytic activity. ECLT testing
showed a hypofibrinolytic state in sepsis, which is in
agreement with our rTPA induced ROTEM assay. D-
dimer levels are determinants of different processes [29],
including the generation of fibrin as well as the rather
nonspecific cleavage of polymerized fibrin molecules by
various enzymes including plasmin but also elastase,
trypsin and others that are released during sepsis by
neutrophils and other inflammatory cells. The high PAI-
1 activity is thought to be primarily responsible for the
attenuated fibrinolysis in patients with sepsis. Transient
Fig. 4 Boxplots of different ROTEM parameters at 175 ng/mL rTPA in healthy volunteers and patient groups. Sepsis and CTS are significantly
different to HV (p < 0.001) for all four parameters. The grey area depicts the 95 % reference ranges as was calculated using the healthy volunteer
data from Table 1. CTS-TXA; cardiothoracic surgery patients using tranexamic acid; HV, healthy volunteers; rTPA, recombinant tissue plasminogen
activator; CT, clotting time; MCF, maximum clot firmness; LOT, lysis onset time; LT, lysis time; FS, fibrinolysis speed, defined as the decline in
%/min between the LOT and LT points; thus: FS = 75/(LTmin-LOTmin); FSc, corrected fibrinolysis speed in mm/min between the LOT and LT points;
thus: FSc = (amplitudeLOT-amplitudeLT)/(LTmin-LOTmin)
Kuiper et al. Thrombosis Journal  (2016) 14:1 Page 8 of 13
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elevation of tPA and PAI-1 exists due to endothelial
damage, but soon after, tPA antigen and activity is low-
ered through inactivation by increasing levels of PAI-1
[30]. Theoretically, upon progression of sepsis and oc-
currence of overt DIC alpha 2-antiplasmin would be
consumed and the ROTEM pattern may change. This
was not found in the early sepsis group and we did not
address conversion to DIC in the present investigation.
In patients with CTS being administered tranexamic
acid a hypofibrinolytic state is observed (reduced FS and
FSc), although an overall reduced maximum clot firm-
ness to start with is present in this group. The ECLT in
this group did not show a hypofibrinolytic state, but ra-
ther a normal state when compared to healthy volun-
teers. The difference between the ECLT and our
ROTEM assay appears to be due to the fact that tranex-
amic acid does not precipitate in the ECLT test [31]. Re-
duced MCF is seen following dilutional effects during
ECC by lowering fibrinogen levels and platelet numbers.
Furthermore, consumption of fibrinogen during cardiac
surgery and the subsequent raised d-dimer levels are
seen in our study. PAI-1 levels are high in our study for
CTS, which, next to tranexamic acid, could strengthen
clot firmness and prevent excessive breakdown by fi-
brinolytic enzymes (which could be reflected by the re-
duced activity of plasminogen) and could counteract the
reduced antifibrinolytic activity of alpha 2-antiplasmin.
Reduced activity of FXIIIa together with a hypofibrinoly-
tic state is seen in CTS [32], which could be the result of
FXIII consumption and dilution. The additional effect of
tranexamic acid resulted in a hypofibrinolytical profile in
our ROTEM assay, while in the one patient not having
had tranexamic acid it showed a normal fibrinolytic pro-
file compared to healthy volunteers. Tranexamic acid
counteracts the effects of ECC induced endogenous tPA
release, caused by shear stress on the vessel wall [33]
and haemodilutional effects of cardiothoracic surgery
[34], and may stabilize clots even more than needed.
Cirrhotic liver disease patients do not seem to differ
from healthy volunteers regarding their global fibrino-
lytic rTPA-ROTEM profile with equal LOT, LT, FS, and
FSc in both rTPA induced conditions together with a
globally reduced procoagulant state. The ECLT was
markedly reduced. Both findings are coherent with other
studies as was researched and discussed previously by
our group [35]. This reset balance in hemostasis is char-
acterized by a reduced level of both the procoagulant
(e.g. fibrinogen) and the antifibrinolytic factors (e.g. low
alpha2-antiplasmin) [36]. tPA is thought to be increasing
over time, while PAI-1 activity levels are decreasing [37].
This could theoretically result in more pronounced
hyperfibrinolysis. High d-dimer levels indicate ongoing
lysis. Again, high d-dimer levels are seen in almost any
thrombotic disease state. Some individuals with cirrhosis
showed very high fibrinolysis speeds (FS), but when
these are corrected for their already reduced MCF, the
corrected fibrinolysis speed (FSc) might give a more ac-
curate view on fibrinolysis potential. The use of the FSc
seem to be more helpful when interpreting fibrinolysis
potentials instead of the FS in assessing the hemostatic
balance by correcting for fibrinogen and platelet counts
which are the main correlates for MCF. Again the 125
ng/ml rTPA concentration might be too high in patients
with hyperfibrinolysis activity and a lower concentration
of rTPA could reveal more pronounced hyperfibrinolysis
in cirrhosis.
Pregnancy is associated with a gradual increase in
PAI-1 over time [38], as confirmed in our study. TAFI
and fibrinogen levels are also higher in comparison to
healthy volunteers [39–41]. tPA activity levels were
lower in comparison to the healthy volunteers, which is
comparable to previous studies [41]. An incline in tPA
levels was shown followed by a drop in tPA levels post-
partum. In our study, reduced tPA levels could result in
higher than normal plasminogen activity. ROTEM
(See figure on previous page.)
Fig. 5 Boxplots of the fibrinolysis determinants and net effect (D-dimer) respectively, in healthy volunteers and patient groups. The grey areas
depict the in house established reference range of fibrinogen and d-dimer levels, while they represent the reference ranges according to the
insert of the manufacturer in the four other parameters. CTS-TXA cardiothoracic surgery patients using tranexamic acid, HV healthy volunteers, rTPA
recombinant tissue plasminogen activator, PAI-1 plasminogen activator inhibitor, TAFI thrombin activated fibrinolysis inhibitor
Fig. 6 Boxplots of euglobulin clotlysis times in healthy volunteers
and patient groups. The grey areas depict the reference range of
euglobulin clotlysis time. CTS-TXA cardiothoracic surgery patients
using tranexamic acid, ECT euglobulin clotlysis time, HV
healthy volunteers
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reference values in pregnancy were established previ-
ously in a study from our clinics and are in line with the
present findings [42]. Hypofibrinolysis on our ROTEM
assay could not be detected, but was clearly present in
the ECLT test.
Fibrinogen levels and also platelet levels seem to cor-
relate well with MCF for any given group, an all-by-all
no new finding [43].
Thus far the test is able to pickup hypofibrinolysis ac-
curately in groups of patients with the 175 ng/mL rTPA
concentration and could guide therapy in CTS and sep-
sis. One could argue that the amount of tranexamic acid
given to CTS patients is too much if even at the high
concentration of rTPA no fibrinolysis is seen within 2 h.
This assay could be used to titrate the drug following
the ROTEM graphs and results in conjunction with clin-
ical relevant outcomes. Trauma induced coagulopathy
(TIC) is a very interesting syndrome in which overt
hyperfbrinolysis is sometimes seen using ROTEM with-
out the need for rTPA addition. As is shown by the
Crash-2 trial [8] the use of tranexamic acid reduces mor-
tality when given within 3 h of the trauma. In our study
a trauma population could not be assessed because of
low numbers of severe trauma patients seen in our hos-
pital during normal operating hours. Much research is
done in this study population using TEG technology
[12]. ROTEM and TEG are essentially the same tech-
niques, but differ slightly in measuring principle, re-
agents used, and naming conventions [43]. In a recent
paper by Moore et al. [44] hyperfibrinolysis seen on
non-rTPA induced TEG analysis was associated with
higher mortality in comparison to a physiological sub-
group, while shutdown of hyperfibrinolysis was associ-
ated with lower mortality rates in comparison to
hyperfibrinolysis, but these still being higher than the
physiological subgroup. This resulted in a U-shaped
optimum curve in which careful titration of tranexamic
acid could result in better survival rates. High mortality
rate due to fibrinolysis shutdown was also found by Raza
et al. [1]. A recent review by Dobson et al. [45] discusses
the timeline in trauma induced coagulopathy and the re-
view by Napolitano et al. [46] extensively researched the
literature to make recommendations regarding tranex-
amic acid use in trauma. For this purpose implementa-
tion of our rTPA-ROTEM assay may shed more light on
this subject matter.
As a limitation, hyperfibrinolysis could not be shown
in a group of patients with cirrhosis when averaging
their results. However, some individual patients do show
a hyperfibrinolytic potential, while others do not. Still,
this assay might be useful for individual patients with
cirrhotic liver disease to diagnose (and treat) hyperfibri-
nolysis, although the rTPA addition needs titrating to a
lower concentration.
Another limitation is the manual pipetting that is re-
quired up till now. Having ready to use solutions and
implementing them together with the automatic pipet-
ting function on the ROTEM device could greatly re-
duce the inter-observer variability, especially for the
clotting times.
Our rTPA induced fibrinolysis ROTEM assay showed
different results in comparison to the ECLT test. This is
because there are essential differences between both
tests. The ECLT is plasma based and due to acidification
of the plasma only few factors are precipitated, the eu-
globulin fraction. As such, the role of red blood cells
and thrombocytes is excluded in the ECLT on fibrinoly-
sis regulation. This makes our test a valuable addition to
the arsenal of fibrinolysis testing.
Conclusions
In conclusion, we developed a reproducible whole blood
rTPA ROTEM assay for diagnosing hypofibrinolytic po-
tential with short turnaround times, which in healthy
volunteers seems to produce acceptable variations
resulting in narrow reference intervals. The 175 ng/ml
rTPA concentration appears to be sensitive for the medi-
cation effect of tranexamic acid on fibrinolysis, which is
in contrast to the ECLT for tranexamic acid. This 175
ng/ml concentration may distinguish a hypo- from a
normofibrinolytic potential. The implementation of this
test needs to be evaluated in more prominent hyperfibri-
nolytic disease states, like trauma or thrombolysis ther-
apy, in order to address the potential utility in the
diagnostic workup of patients with fibrinolytic dysfunc-
tion, as well as in guiding anti-fibrinolytic management.
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